 |
110 Diseases |  |
151 Trials |
|
151 Trials |  |
7120 News |  |
| «12...7576777879808182838485...8687» |
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial completion date: ProliaHip: Denosumab in Enhancement of Bone Bonding of Hip Prosthesis in Postmenopausal Women (clinicaltrials.gov) - Apr 30, 2018
P4, N=65, Completed, Sponsor: Turku University Hospital
Trial completion date: Aug 2016 --> Dec 2017
- Prolia (denosumab) / Amgen
Trial completion date, Trial termination: Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE) (clinicaltrials.gov) - Apr 24, 2018
P3, N=4509, Terminated, Sponsor: Amgen
Trial completion date: Aug 2022 --> Mar 2018 | Active, not recruiting --> Terminated; Terminated: Amgen decision following Primary Analysis. Not due to safety reason
- | Prolia (denosumab) / Amgen
Enrollment open: Bisphosphonates for Prevention of Post-Denosumab Bone Loss (clinicaltrials.gov) - Apr 17, 2018
P2, N=34, Recruiting, Sponsor: Columbia University
Not due to safety reason Not yet recruiting --> Recruiting
- |||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial completion date, Trial primary completion date: Multicenter,Single-arm Study to Evaluate Efficacy, Safety, & Pharmacokinetics of Denosumab in Children w/ OI (clinicaltrials.gov) - Mar 30, 2018
P3, N=150, Recruiting, Sponsor: Amgen
Not yet recruiting --> Recruiting Trial completion date: Aug 2021 --> Jan 2022 | Trial primary completion date: Aug 2019 --> Jan 2020
- | Prolia (denosumab) / Amgen, GSK, Daiichi Sankyo
Journal: Symplastic/pseudoanaplastic giant cell tumor of the bone. (Pubmed Central) - Mar 23, 2018
GCTB with symplastic/pseudoanaplastic change is an uncommon variant of conventional GCTB, which can mimic primary sarcoma or sarcomatous transformation. These tumors possess the same missense mutation in histone H3.3 as conventional GCTB.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
New P4 trial: MiDeTe - microRNA Levels Under Denosumab and Teriparatide Therapy in Postmenopausal Osteoporosis (clinicaltrials.gov) - Mar 20, 2018
P4, N=80, Recruiting, Sponsor: Medical University of Vienna
- Prolia (denosumab) / Amgen, Daiichi Sankyo
Phase classification, Trial completion date, Trial primary completion date: Denosumab Administration After Spinal Cord Injury (clinicaltrials.gov) - Mar 12, 2018
P4, N=24, Recruiting, Sponsor: James J. Peters Veterans Affairs Medical Center
These tumors possess the same missense mutation in histone H3.3 as conventional GCTB. Phase classification: P2 --> P4 | Trial completion date: May 2018 --> May 2019 | Trial primary completion date: May 2017 --> May 2019
- || Prolia (denosumab) / Amgen
Trial completion date, Trial primary completion date: Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004 (clinicaltrials.gov) - Mar 12, 2018
P4, N=150, Recruiting, Sponsor: Amgen
Phase classification: P2 --> P4 | Trial completion date: May 2018 --> May 2019 | Trial primary completion date: May 2017 --> May 2019 Trial completion date: Jan 2023 --> Apr 2023 | Trial primary completion date: Jan 2023 --> Apr 2023
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial completion date, Trial initiation date, Trial primary completion date: DOHA: Denosumab Versus Zoledronic Acid in Thalassemia-Induced Osteoporosis (clinicaltrials.gov) - Mar 8, 2018
P3, N=20, Not yet recruiting, Sponsor: Hamad Medical Corporation
Trial completion date: Jan 2023 --> Apr 2023 | Trial primary completion date: Jan 2023 --> Apr 2023 Trial completion date: Apr 2018 --> Jul 2019 | Initiation date: Sep 2017 --> May 2018 | Trial primary completion date: Jan 2018 --> May 2019
- | Prolia (denosumab) / Amgen
Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date: DenosuMast: Interest of Denosumab Treatment in Osteoporosis Associated to Systemic Mastocytosis (clinicaltrials.gov) - Mar 8, 2018
P3, N=90, Recruiting, Sponsor: Assistance Publique - H
Trial completion date: Apr 2018 --> Jul 2019 | Initiation date: Sep 2017 --> May 2018 | Trial primary completion date: Jan 2018 --> May 2019 Not yet recruiting --> Recruiting | Trial completion date: Jan 2023 --> Mar 2023 | Initiation date: Jan 2018 --> Mar 2018 | Trial primary completion date: Jan 2021 --> Mar 2021
- | Prolia (denosumab) / Amgen, Kineret (anakinra) / SOBI
Enrollment closed, Enrollment change, Trial completion date, Trial initiation date, Trial primary completion date, Combination therapy, Metastases: NCI-2018-01842: Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers (clinicaltrials.gov) - Mar 7, 2018
P1, N=57, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting | Trial completion date: Jan 2023 --> Mar 2023 | Initiation date: Jan 2018 --> Mar 2018 | Trial primary completion date: Jan 2021 --> Mar 2021 Recruiting --> Active, not recruiting | N=147 --> 57 | Trial completion date: Jun 2019 --> Jun 2021 | Initiation date: Jun 2012 --> Jun 2012 | Trial primary completion date: Jun 2019 --> Jun 2020
- ||||| Prolia (denosumab) / Amgen
Trial initiation date: Safety and Efficiency of Denosumab in Pediatric Subjects With Glucocorticoid-induced Osteoporosis (clinicaltrials.gov) - Mar 3, 2018
P3, N=150, Not yet recruiting, Sponsor: Amgen
Recruiting --> Active, not recruiting | N=147 --> 57 | Trial completion date: Jun 2019 --> Jun 2021 | Initiation date: Jun 2012 --> Jun 2012 | Trial primary completion date: Jun 2019 --> Jun 2020 Initiation date: Jan 2018 --> Apr 2018
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial completion date, Trial primary completion date: REaCT-BTA: 4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases (clinicaltrials.gov) - Mar 2, 2018
P4, N=250, Recruiting, Sponsor: Ottawa Hospital Research Institute
Initiation date: Jan 2018 --> Apr 2018 Trial primary completion date: Apr 2018 --> Apr 2019 | Trial completion date: Apr 2019 --> Apr 2020
- | Prolia (denosumab) / Amgen
Enrollment open: The Efficacy of Denosumab in Incomplete Patients Spinal Cord Injury (clinicaltrials.gov) - Mar 1, 2018
P4, N=32, Recruiting, Sponsor: James J. Peters Veterans Affairs Medical Center
Trial primary completion date: Apr 2018 --> Apr 2019 | Trial completion date: Apr 2019 --> Apr 2020 Not yet recruiting --> Recruiting
- ||||| Prolia (denosumab) / Amgen
Enrollment closed, Enrollment change, Metastases: SPLENDOUR: Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy (clinicaltrials.gov) - Feb 20, 2018
P3, N=514, Active, not recruiting, Sponsor: European Thoracic Oncology Platform
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=1000 --> 514
- | Boyoubei (denosumab biosimilar) / Luye Group
New P1 trial: A Study to Evaluate the Denosumab in Healthy Adults (clinicaltrials.gov) - Feb 9, 2018
P1, N=32, Recruiting, Sponsor: Luye Pharma Group Ltd.
- |||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial primary completion date, Metastases: Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer (clinicaltrials.gov) - Feb 1, 2018
P3, N=129, Active, not recruiting, Sponsor: Amgen
Recruiting --> Active, not recruiting | N=1000 --> 514 Trial primary completion date: Mar 2018 --> Sep 2018
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial initiation date: Observational Study of Denosumab (Prolia (clinicaltrials.gov) - Jan 30, 2018
P=N/A, N=1501, Completed, Sponsor: Amgen
Trial primary completion date: Mar 2018 --> Sep 2018 Initiation date: Nov 2012 --> Nov 2011
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
New P1/2 trial: Deno-ABC: Denosumab: A Potential Treatment Option for Aneurysmal Bone Cysts (clinicaltrials.gov) - Jan 30, 2018
P1/2, N=6, Completed, Sponsor: Peking University People's Hospital
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial primary completion date: TNFSF11 Inhibition and Fertility: a Prospective Study (clinicaltrials.gov) - Jan 29, 2018
P2, N=15, Active, not recruiting, Sponsor: Martin Blomberg Jensen
Initiation date: Nov 2012 --> Nov 2011 Trial primary completion date: Feb 2016 --> Feb 2017
- Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial completion: Bone Histomorphometry in Postmenopausal Men and Women With Osteoarthritis Undergoing Total Hip Replacement (clinicaltrials.gov) - Jan 29, 2018
P4, N=6, Completed, Sponsor: Amgen
Trial primary completion date: Feb 2016 --> Feb 2017 Active, not recruiting --> Completed
- | Prolia (denosumab) / Amgen, Xofigo (radium Ra-223 dichloride) / Bayer
Enrollment closed, Enrollment change, Trial primary completion date, Combination therapy, Metastases: Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer (clinicaltrials.gov) - Jan 26, 2018
P2, N=45, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=36 --> 45 | Trial primary completion date: Feb 2019 --> Feb 2020
- | Prolia (denosumab) / Amgen
New P3 trial: MOSCAR: Efficacy and Safety of Systemic Treatments of Bone Metastases From Kidney Cancer in Patients Treated With Targeted Therapies (clinicaltrials.gov) - Jan 24, 2018
P3, N=216, Not yet recruiting, Sponsor: Centre Leon Berard
- | Prolia (denosumab) / Amgen, GSK, Daiichi Sankyo
Clinical, Journal: Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients With Advanced Cancer and Bone Metastases Treated With Bone Antiresorptive Agents. (Pubmed Central) - Jan 21, 2018
Assessment of uNTx and sBSAP levels after bone antiresorptive therapy may add to identification of patients at risk for worse clinical outcomes. Clin Cancer Res; 22(23); 5713-21.
- ||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment closed: Treatment With Zoledronic Acid Subsequent to Denosumab in Osteoporosis (clinicaltrials.gov) - Jan 17, 2018
P4, N=60, Active, not recruiting, Sponsor: Aarhus University Hospital
Clin Cancer Res; 22(23); 5713-21. Recruiting --> Active, not recruiting
- | Prolia (denosumab) / Amgen
New P3 trial: DenosuMast: Interest of Denosumab Treatment in Osteoporosis Associated to Systemic Mastocytosis (clinicaltrials.gov) - Jan 16, 2018
P3, N=90, Not yet recruiting, Sponsor: Assistance Publique - H
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment closed: AfterDmab: Zoledronic Acid to Maintain Bone Mass After Denosumab Discontinuation (clinicaltrials.gov) - Jan 10, 2018
P4, N=90, Active, not recruiting, Sponsor: 424 General Military Hospital
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Clinical, Journal: Comparative Safety and Effectiveness of Denosumab Versus Zoledronic Acid in Patients With Osteoporosis: A Cohort Study. (Pubmed Central) - Jan 10, 2018
The risk of osteoporotic fracture was also similar between groups (HR 1.21, 95% CI 0.84-1.73). This large population-based cohort study shows that denosumab and zoledronic acid have comparable clinical safety and effectiveness with regard to the risk of serious infection, CVD and osteoporosis fracture within 365 days after initiation of medications.
- | Prolia (denosumab) / Amgen
New P2 trial: Bisphosphonates for Prevention of Post-Denosumab Bone Loss (clinicaltrials.gov) - Jan 10, 2018
P2, N=34, Not yet recruiting, Sponsor: Columbia University
- Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment closed, Enrollment change: Bone Histomorphometry in Postmenopausal Men and Women With Osteoarthritis Undergoing Total Hip Replacement (clinicaltrials.gov) - Jan 9, 2018
P4, N=6, Active, not recruiting, Sponsor: Amgen
This large population-based cohort study shows that denosumab and zoledronic acid have comparable clinical safety and effectiveness with regard to the risk of serious infection, CVD and osteoporosis fracture within 365 days after initiation of medications. Recruiting --> Active, not recruiting | N=15 --> 6
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Phase classification: Osteoclast Inhibition and Bone Formation (clinicaltrials.gov) - Jan 5, 2018
P1, N=81, Completed, Sponsor: Mayo Clinic
Recruiting --> Active, not recruiting | N=15 --> 6 Phase classification: P=N/A --> P1
- |||| Prolia (denosumab) / Amgen
Trial completion, Combination therapy, Metastases: Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov) - Jan 4, 2018
P2, N=226, Completed, Sponsor: Amgen
Phase classification: P=N/A --> P1 Active, not recruiting --> Completed
- Prolia (denosumab) / Amgen, Daiichi Sankyo
Biomarker, Enrollment closed, Enrollment change: Denosumab for Breast Cancer With Bone Mets (clinicaltrials.gov) - Jan 3, 2018
P2, N=7, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=35 --> 7
- | Prolia (denosumab) / Amgen
Enrollment change, Trial termination, Trial primary completion date, IO biomarker: D-Beyond: A Study to Evaluate Denosumab in Young Patients With Primary Breast Cancer (clinicaltrials.gov) - Dec 29, 2017
P2, N=27, Terminated, Sponsor: Jules Bordet Institute
Recruiting --> Active, not recruiting | N=35 --> 7 N=39 --> 27 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2016 --> Dec 2017; Poor recruitment
- | Tymlos (abaloparatide) / Radius, Teijin, Prolia (denosumab) / Amgen, Daiichi Sankyo, Evenity (romosozumab) / Astellas, Amgen, UCB
Clinical, Journal, HEOR: A Model for Assessing the Clinical and Economic Benefits of Bone-Forming Agents for Reducing Fractures in Postmenopausal Women at High, Near-Term Risk of Osteoporotic Fracture. (Pubmed Central) - Dec 27, 2017
Incorporating time-specific fracture effects in the Markov cohort model allowed for estimation of a range of cost savings, quality-adjusted life years gained, and clinical fractures avoided at different levels of fracture protection onset and magnitude. Results provide a first estimate of the potential "value" new bone-forming agents (romosozumab and abaloparatide) may confer relative to teriparatide.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial primary completion date: Knee Osteoarthritis Outcome Measures in Arthritic Patients With Osteoporosis (clinicaltrials.gov) - Dec 22, 2017
P=N/A, N=20, Enrolling by invitation, Sponsor: Edward Fox
Results provide a first estimate of the potential "value" new bone-forming agents (romosozumab and abaloparatide) may confer relative to teriparatide. Trial primary completion date: Dec 2018 --> Dec 2020
- ||||| Prolia (denosumab) / Amgen
New P2 trial: Denosumab as an add-on Neoadjuvant Treatment (GeparX) (clinicaltrials.gov) - Dec 20, 2017
P2, N=778, Not yet recruiting, Sponsor: German Breast Group
- |||| Prolia (denosumab) / Amgen, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment open, Trial primary completion date, Checkpoint inhibition: CHARLI: Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma (clinicaltrials.gov) - Dec 18, 2017
P1/2, N=72, Recruiting, Sponsor: Australia and New Zealand Melanoma Trials Group
Trial primary completion date: Dec 2018 --> Dec 2020 Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2019 --> Jun 2021 | Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2019 --> Jun 2021 | Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2019 --> Jun 2021
- |||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial primary completion date, Metastases: Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer (clinicaltrials.gov) - Dec 15, 2017
P3, N=129, Active, not recruiting, Sponsor: Amgen
Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2019 --> Jun 2021 | Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2019 --> Jun 2021 | Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2019 --> Jun 2021 Trial primary completion date: Dec 2017 --> Mar 2018
- |||| Prolia (denosumab) / Amgen
Enrollment open: Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004 (clinicaltrials.gov) - Dec 13, 2017
P4, N=150, Recruiting, Sponsor: Amgen
Trial primary completion date: Dec 2017 --> Mar 2018 Not yet recruiting --> Recruiting
- |||| Prolia (denosumab) / Amgen, Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open: KEYPAD: Denosumab and Pembrolizumab in Clear Cell Renal Carcinoma (clinicaltrials.gov) - Dec 13, 2017
P2, N=70, Recruiting, Sponsor: Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal: Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update. (Pubmed Central) - Dec 10, 2017
Evidence is insufficient to support the use of one BMA over another. Additional information is available at www.asco.org/breast-cancer-guidelines and www.asco.org/guidelineswiki .
- || Prolia (denosumab) / Amgen
Trial primary completion date: Denosumab Safety Assessment in Multiple Observational Databases (clinicaltrials.gov) - Dec 7, 2017
P=N/A, N=575462, Active, not recruiting, Sponsor: Amgen
Additional information is available at www.asco.org/breast-cancer-guidelines and www.asco.org/guidelineswiki . Trial primary completion date: May 2023 --> May 2020
- | Prolia (denosumab) / Amgen
New trial: Safety and Efficacy of Post-operative Denosumab Strategy for Giant Cell Tumor of Bone Treatment in China (clinicaltrials.gov) - Nov 30, 2017
P=N/A, N=100, Not yet recruiting, Sponsor: Peking University People's Hospital
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial primary completion date: Study of Denosumab in Subjects With Giant Cell Tumor of Bone (clinicaltrials.gov) - Nov 27, 2017
P2, N=536, Active, not recruiting, Sponsor: Amgen
Trial primary completion date: May 2023 --> May 2020 Trial primary completion date: Nov 2017 --> May 2018
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial primary completion date: Denosumab for the Treatment of Osteoporosis in Children: A Pilot Study (clinicaltrials.gov) - Nov 27, 2017
P2, N=20, Recruiting, Sponsor: Children's Hospital of Eastern Ontario
Trial primary completion date: Nov 2017 --> May 2018 Trial primary completion date: Mar 2018 --> Mar 2019
- || Prolia (denosumab) / Amgen
Trial primary completion date: RANKL-blockade for the Treatment of Erosive Osteoarthritis (OA) of Interphalangeal Finger Joints (clinicaltrials.gov) - Nov 7, 2017
P2, N=100, Recruiting, Sponsor: University Hospital, Ghent
Trial primary completion date: Mar 2018 --> Mar 2019 Trial primary completion date: Jan 2018 --> Sep 2018
- ||| Prolia (denosumab) / Amgen, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Checkpoint inhibition: CHARLI: Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma (clinicaltrials.gov) - Nov 6, 2017
P1/2, N=72, Not yet recruiting, Sponsor: Australia and New Zealand Melanoma Trials Group
Trial primary completion date: Jan 2018 --> Sep 2018 Initiation date: Sep 2017 --> Nov 2017
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment open: Knee Osteoarthritis Outcome Measures in Arthritic Patients With Osteoporosis (clinicaltrials.gov) - Oct 31, 2017
P=N/A, N=20, Enrolling by invitation, Sponsor: Edward Fox
Initiation date: Sep 2017 --> Nov 2017 Not yet recruiting --> Enrolling by invitation
- | Prolia (denosumab) / Amgen
New P3 trial: Efficacy of Denosumab on Normal BMD in Women Receiving Adjuvant Aromatase Inhibitors for Early Breast Cancer (clinicaltrials.gov) - Oct 30, 2017
P3, N=160, Recruiting, Sponsor: Kyoto Prefectural University of Medicine